These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19663893)

  • 1. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation.
    Benfield MR; Bartosh S; Ikle D; Warshaw B; Bridges N; Morrison Y; Harmon W
    Am J Transplant; 2010 Jan; 10(1):81-8. PubMed ID: 19663893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.
    McDonald RA; Smith JM; Ho M; Lindblad R; Ikle D; Grimm P; Wyatt R; Arar M; Liereman D; Bridges N; Harmon W;
    Am J Transplant; 2008 May; 8(5):984-9. PubMed ID: 18416737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
    Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Chakrabarti P; Wong HY; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Hakala TR; Fung JJ; Simmons RL; Starzl TE; Shapiro R
    Transplantation; 2000 Sep; 70(5):760-4. PubMed ID: 11003353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil.
    Höcker B; Weber LT; Feneberg R; Drube J; John U; Fehrenbach H; Pohl M; Zimmering M; Fründ S; Klaus G; Wühl E; Tönshoff B
    Transplantation; 2009 Mar; 87(6):934-41. PubMed ID: 19300199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis.
    Tsampalieros A; Knoll GA; Molnar AO; Fergusson N; Fergusson DA
    Transplantation; 2017 Apr; 101(4):694-703. PubMed ID: 27736823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal.
    Gaber AO; Moore LW; Alloway RR; Woodle ES; Pirsch J; Shihab F; Henning A; Fitzsimmons W; Holman J; Reisfield R; First MR;
    Transplantation; 2013 Feb; 95(4):573-9. PubMed ID: 23423269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-Sparing and Steroid-Based Immunosuppression in Kidney Transplant: Is There a Difference in Outcomes and Recipient Comorbidities?
    Ahmad N; Khan TFT; Nadeem N; Fourtounas K
    Exp Clin Transplant; 2020 Oct; 18(5):572-576. PubMed ID: 32635885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients.
    Meadows HB; Taber DJ; Pilch NA; Tischer SM; Baliga PK; Chavin KD
    Transplant Proc; 2012 Jun; 44(5):1323-8. PubMed ID: 22664009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid withdrawal in renal transplantation.
    Grenda R
    Pediatr Nephrol; 2013 Nov; 28(11):2107-12. PubMed ID: 23288351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.